Riskpilot← Back to searchSign inGet full accessCurera ReDoc AB
ABActiveOrg 5567841126Gamla Landsvägen 94General medical practice activities · NACE 8621Est. 20090 employees
Revenue 2025
SEK 427K
+109% vs 2024
EBITDA margin
36.4%
+263% vs 2024
Equity ratio
79.8%
Financial strength
Net profit 2025
SEK 439K
+423% vs 2024
| Revenue | SEK 427K | +109% |
| EBITDA | SEK 155K | +263% |
| Net profit | SEK 439K | +423% |
| Total assets | SEK 3M | +20% |
| Equity | SEK 2,4M | +9% |
| Employees | 0 | — |
Legal name
Curera ReDoc AB
Org number
5567841126
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
16 juni 2009
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva försäkringsmedicinska och rehabiliteringsmedicinska bedömningar och utlåtande, specialistläkarverksamhet inom öppen och sluten vård samt förvaltning av värdepapper. Föreläsningar, utbildning och rådgivning inom arbetsmiljö och hälsovård samt företagshälsovård jämte därmed förenlig verksamhet.
Address
Gamla Landsvägen 94
Email
curera@cureraredoc.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 850 | 640 | 203 | 204 | 427 |
| Staff expenses | — | — | −78 | −51 | −62 |
| EBITDA | 393 | 231 | −93 | −95 | 155 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 393 | 231 | −93 | −95 | 155 |
| Net financials | 384 | 5 | 30 | 14 | 581 |
| Profit before tax | 587 | 346 | 282 | 114 | 557 |
| Tax | −125 | −77 | −66 | −30 | −117 |
| Net profit | 462 | 269 | 216 | 84 | 439 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 100 | 3 249 | 2 802 | 2 492 | 2 982 |
| Equity | 2 202 | 2 290 | 2 307 | 2 191 | 2 380 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 59 | 229 | 110 | 111 | 232 |
| Total debt | 59 | 229 | 110 | 111 | 232 |
EBITDA margin
36.4%
This company
15.8%
Market median
+130% vs market
20212025
Equity ratio
79.8%
This company
38.2%
Market median
+109% vs market
20212025
Return on equity
18.5%
This company
18.4%
Market median
+1% vs market
20212025
Net profit margin
102.8%
This company
8.1%
Market median
+1169% vs market
20212025
Asset turnover
0.14×
This company
1.12×
Market median
-88% vs market
20212025
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DG Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
| Former (1) | ||
| Chairman | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Curera ReDoc AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dan Georg Stefan Lundqvist | Chief Executive Officer | 0 companies |
| Malin Veronica Lundqvist Ståhl | Chairman | 0 companies |
| Lars Martin Johannes Lundqvist | Deputy Board Member | 0 companies |